Gnashing of teeth after yet another non-starter in NASH

25 June 2019

Another trial failure in non-alcoholic steatohepatitis (NASH) sent shares in Californian firm Conatus Pharmaceuticals (Nasdaq: CNAT) cratering on Monday, with results showing that the ENCORE-LF trial missed its primary endpoint.

It is the latest in a series of disappointments for NASH therapy bulls, after CymaBay Therapeutics’ (Nasdaq: CBAY) miss with seladelpar, an unclear picture for Intercept Pharmaceuticals' (Nasdaq: ICPT) obeticholic acid, and Gilead Science’s (Nasdaq: GILD) high profile failure with selonsertib.

Conatus stock fell over 60% after the firm released data from the Phase IIb study of its lead candidate emricasan on Monday, confirming efficacy endpoints were not met.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK